Skip to main content

Table 1 Baseline clinicopathologic characteristics in ALK-rearranged patients with advanced non-small-cell lung cancer treated with crizotinib

From: Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Characteristic

No. of Patients (%)

P-value

ALK + c-Met-

(n = 101)

ALK + c-Met+

(n = 15)

 

Age, years

 Median

50

44

0.551

 Range

25–79

24–75

 

Gender

 Male

45 (44.6%)

7(46.7%)

1.000

 Female

56(55.4%)

8(53.3%)

 

ECOG PS

 0–1

88(84.9%)

15(100.0%)

0.213

  ≥ 2

13(15.1%)

0(0.0%)

 

Smoking status

 Non-smoker

83(82.2%)

14(93.3%)

0.460

 Smoker

18(17.8%)

1(6.7%)

 

Histology

 Adenocarcinoma

98(97.0%)

14(93.3%)

0.228

 Others

3(3.0%)

1(6.7%)

 

Clinical staging

 IIIB

5(5.9%)

0(0.0%)

1.000

 IV

96(94.1%)

15(100.0%)

 

Lines of crizotinib

 1st-line

52(51.5%)

7(46.7%)

0.787

 2nd-or further-lines

49(48.5%)

8(53.3%)

 
  1. Abbreviations: ALK anaplastic lymphoma kinase, c-Met cellular-mesenchymal-epithelial transition, ALK + c-Met+ patients with ALK rearrangement and c-Met overexpression positive, ALK + c-Met- patients with ALK rearrangement and c-Met overexpression negative, ECOG PS Eastern Cooperative Oncology Group performance status. Cinical staging was classified based on American Joint Committee on Cancer 7th edition